Bringing the fundamentals into focus…
Back to Takeda Pharmaceutical Company Limited
How Takeda Pharmaceutical Company Limited stacks up
TAK · against 53 other Healthcare companies of similar size
Valuation
44/ 100
Near the bottom of its peers.
Ranked #48 of 54 · scores higher than 11% of peers
Bars: peers in each 10-point band of the valuation score7 peers with a valuation score of 40–49, including TAK · Click a bar to see the companies
Why valuation scores 44?
Weighted metrics compared with all Healthcare companies.A mix: stronger free cash flow yield and EBITDA yield, but weaker earnings yield than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -1.4% vs peer median 1.5%
- more operating profit (EBITDA) for the company's total value: stronger than 74% of peers. EBITDA yield: 4.9% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 77% of peers. Free cash flow yield: 8.1% vs peer median 0.0%
Metric by metric
Position: dot = TAK, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | TAK | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 52 reported | Not reported | 3.0% | — | — | 30% |
| EBITDA yieldHigher is better · 55 reported | 8.0% | 6.2% | 76% | 50% | |
| Free cash flow yieldHigher is better · 41 reported | 4.6% | 3.9% | 57% | 20% | |
| Book yieldHigher is better · 51 reported | 71.0% | 22.1% | 98% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around TAK| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 78.1B USD | 89 | 60 | |
| 2 | 108.6B USD | 88 | 66 | |
| 3 | 97.5B USD | 87 | 67 | |
| 4 | 6.17T JPY (≈$42.0B) | 86 | 70 | |
| 5 | 45.9B USD | 84 | 61 | |
| 43 | 52.9B USD | 49 | 57 | |
| 45 | 54.9B USD | 47 | 59 | |
| 46 | 40.2B USD | 46 | 73 | |
| 46 | 49.1B USD | 46 | 69 | |
| 48 | 66.3B USD | 44 | 30 | |
| 49 | 56.7B USD | 42 | 79 | |
| 50 | 45.2B USD | 38 | 46 | |
| 51 | 33.3B USD | 8 | 24 | |
| 51 | 91.2B USD | 8 | 18 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score